vs
Side-by-side financial comparison of Gilead Sciences (GILD) and PILGRIMS PRIDE CORP (PPC). Click either name above to swap in a different company.
Gilead Sciences is the larger business by last-quarter revenue ($7.9B vs $4.5B, roughly 1.7× PILGRIMS PRIDE CORP). Gilead Sciences runs the higher net margin — 27.5% vs 2.2%, a 25.3% gap on every dollar of revenue. On growth, Gilead Sciences posted the faster year-over-year revenue change (4.7% vs 1.6%). Over the past eight quarters, Gilead Sciences's revenue compounded faster (8.9% CAGR vs -0.3%).
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
Pilgrim's Pride Corporation is an American, multi-national food company, currently one of the largest chicken producers in the United States and Puerto Rico and the second-largest chicken producer in Mexico. It exited bankruptcy in December 2009 and relocated its U.S. headquarters to Greeley, Colorado, in 2011. It is majority-owned by JBS S.A. Pilgrim's Pride purchased Gold'n Plump for $350 million in late November 2016.
GILD vs PPC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $7.9B | $4.5B |
| Net Profit | $2.2B | $101.5M |
| Gross Margin | 79.5% | 7.6% |
| Operating Margin | 25.0% | 3.6% |
| Net Margin | 27.5% | 2.2% |
| Revenue YoY | 4.7% | 1.6% |
| Net Profit YoY | 22.4% | — |
| EPS (diluted) | $1.75 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $4.5B | ||
| Q4 25 | $7.9B | $4.5B | ||
| Q3 25 | $7.8B | $4.8B | ||
| Q2 25 | $7.1B | $4.8B | ||
| Q1 25 | $6.7B | $4.5B | ||
| Q4 24 | $7.6B | $4.4B | ||
| Q3 24 | $7.5B | $4.6B | ||
| Q2 24 | $7.0B | $4.6B |
| Q1 26 | — | $101.5M | ||
| Q4 25 | $2.2B | $88.0M | ||
| Q3 25 | $3.1B | $342.8M | ||
| Q2 25 | $2.0B | $355.5M | ||
| Q1 25 | $1.3B | $296.0M | ||
| Q4 24 | $1.8B | $235.9M | ||
| Q3 24 | $1.3B | $349.9M | ||
| Q2 24 | $1.6B | $326.3M |
| Q1 26 | — | 7.6% | ||
| Q4 25 | 79.5% | 9.5% | ||
| Q3 25 | 79.8% | 13.9% | ||
| Q2 25 | 78.8% | 15.0% | ||
| Q1 25 | 76.9% | 12.4% | ||
| Q4 24 | 79.1% | 12.7% | ||
| Q3 24 | 79.1% | 14.9% | ||
| Q2 24 | 77.8% | 15.2% |
| Q1 26 | — | 3.6% | ||
| Q4 25 | 25.0% | 4.5% | ||
| Q3 25 | 42.8% | 10.4% | ||
| Q2 25 | 34.9% | 10.8% | ||
| Q1 25 | 33.6% | 9.1% | ||
| Q4 24 | 32.4% | 7.0% | ||
| Q3 24 | 11.8% | 11.1% | ||
| Q2 24 | 38.0% | 9.7% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | 27.5% | 1.9% | ||
| Q3 25 | 39.3% | 7.2% | ||
| Q2 25 | 27.7% | 7.5% | ||
| Q1 25 | 19.7% | 6.6% | ||
| Q4 24 | 23.6% | 5.4% | ||
| Q3 24 | 16.6% | 7.6% | ||
| Q2 24 | 23.2% | 7.2% |
| Q1 26 | — | $0.43 | ||
| Q4 25 | $1.75 | $0.37 | ||
| Q3 25 | $2.43 | $1.44 | ||
| Q2 25 | $1.56 | $1.49 | ||
| Q1 25 | $1.04 | $1.24 | ||
| Q4 24 | $1.43 | $1.00 | ||
| Q3 24 | $1.00 | $1.47 | ||
| Q2 24 | $1.29 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $68.0M | $542.4M |
| Total DebtLower is stronger | $24.9B | $3.1B |
| Stockholders' EquityBook value | $22.7B | $3.7B |
| Total Assets | $59.0B | $10.2B |
| Debt / EquityLower = less leverage | 1.10× | 0.83× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $542.4M | ||
| Q4 25 | $68.0M | $640.2M | ||
| Q3 25 | $19.0M | $612.6M | ||
| Q2 25 | $69.0M | $849.0M | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $1.9B | ||
| Q2 24 | — | $1.3B |
| Q1 26 | — | $3.1B | ||
| Q4 25 | $24.9B | $3.1B | ||
| Q3 25 | $24.9B | $3.1B | ||
| Q2 25 | $24.9B | $3.1B | ||
| Q1 25 | $25.0B | $3.2B | ||
| Q4 24 | $26.7B | $3.2B | ||
| Q3 24 | $23.2B | $3.2B | ||
| Q2 24 | $23.3B | $3.2B |
| Q1 26 | — | $3.7B | ||
| Q4 25 | $22.7B | $3.7B | ||
| Q3 25 | $21.5B | $3.5B | ||
| Q2 25 | $19.7B | $3.7B | ||
| Q1 25 | $19.2B | $3.1B | ||
| Q4 24 | $19.3B | $4.2B | ||
| Q3 24 | $18.5B | $4.2B | ||
| Q2 24 | $18.3B | $3.7B |
| Q1 26 | — | $10.2B | ||
| Q4 25 | $59.0B | $10.3B | ||
| Q3 25 | $58.5B | $10.0B | ||
| Q2 25 | $55.7B | $10.1B | ||
| Q1 25 | $56.4B | $11.0B | ||
| Q4 24 | $59.0B | $10.7B | ||
| Q3 24 | $54.5B | $10.7B | ||
| Q2 24 | $53.6B | $10.1B |
| Q1 26 | — | 0.83× | ||
| Q4 25 | 1.10× | 0.84× | ||
| Q3 25 | 1.16× | 0.87× | ||
| Q2 25 | 1.27× | 0.83× | ||
| Q1 25 | 1.30× | 1.02× | ||
| Q4 24 | 1.38× | 0.76× | ||
| Q3 24 | 1.26× | 0.76× | ||
| Q2 24 | 1.28× | 0.85× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.3B | — |
| Free Cash FlowOCF − Capex | $3.1B | — |
| FCF MarginFCF / Revenue | 39.4% | — |
| Capex IntensityCapex / Revenue | 2.6% | — |
| Cash ConversionOCF / Net Profit | 1.52× | — |
| TTM Free Cash FlowTrailing 4 quarters | $9.5B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.3B | $291.2M | ||
| Q3 25 | $4.1B | $458.3M | ||
| Q2 25 | $827.0M | $495.2M | ||
| Q1 25 | $1.8B | $126.9M | ||
| Q4 24 | $3.0B | $349.3M | ||
| Q3 24 | $4.3B | $651.1M | ||
| Q2 24 | $1.3B | $718.6M |
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | $10.0M | ||
| Q3 25 | $4.0B | $275.9M | ||
| Q2 25 | $720.0M | $339.1M | ||
| Q1 25 | $1.7B | $28.1M | ||
| Q4 24 | $2.8B | $176.6M | ||
| Q3 24 | $4.2B | $565.3M | ||
| Q2 24 | $1.2B | $617.7M |
| Q1 26 | — | — | ||
| Q4 25 | 39.4% | 0.2% | ||
| Q3 25 | 51.0% | 5.8% | ||
| Q2 25 | 10.2% | 7.1% | ||
| Q1 25 | 24.8% | 0.6% | ||
| Q4 24 | 37.4% | 4.0% | ||
| Q3 24 | 55.2% | 12.3% | ||
| Q2 24 | 17.2% | 13.5% |
| Q1 26 | — | — | ||
| Q4 25 | 2.6% | 6.2% | ||
| Q3 25 | 1.9% | 3.8% | ||
| Q2 25 | 1.5% | 3.3% | ||
| Q1 25 | 1.6% | 2.2% | ||
| Q4 24 | 1.9% | 4.0% | ||
| Q3 24 | 1.9% | 1.9% | ||
| Q2 24 | 1.9% | 2.2% |
| Q1 26 | — | — | ||
| Q4 25 | 1.52× | 3.31× | ||
| Q3 25 | 1.35× | 1.34× | ||
| Q2 25 | 0.42× | 1.39× | ||
| Q1 25 | 1.34× | 0.43× | ||
| Q4 24 | 1.67× | 1.48× | ||
| Q3 24 | 3.44× | 1.86× | ||
| Q2 24 | 0.82× | 2.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
PPC
| U.S | $2.6B | 58% |
| Europe | $1.4B | 30% |
| Mexico | $545.5M | 12% |
